Clever Leaves Holdings Inc.
CLVR Healthcare Drug Manufacturers Specialty & Generic
Clever Leaves Holdings Inc.’s revenue for fiscal 2023 (year ended December 2023) was $17.4 million, up 6.14% from fiscal 2022. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow CLVR
Clever Leaves Holdings Inc. (CLVR) EV/Sales
As of 15 October 2026, Clever Leaves Holdings Inc. (CLVR) trades at a EV/Sales of −0.3×. Over the past ten years it has ranged from −0.3× (October 2026) to 21.5× (May 2021); the current reading is higher than 27% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −0.1× | — |
| FY2022 | 0.1× | (98.70%) |
| FY2021 | 4.4× | 4.38% |
| FY2020 | 4.2× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2023 | −0.1× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.3× | (56.40%) |
| Mar 2023 | 0.8× | 1,226.46% |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CLVR Clever Leaves Holdings Inc. | −0.3× |
| BGM BGM Group Ltd. compare | −0.1× |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| CTOR Citius Oncology, Inc. compare | n/m |
| ORGO Organogenesis compare | 0.2× |
| OGI Organigram Global Inc. compare | 0.6× |
| PROCF Sofgen Pharma S.A compare | 0.7× |
| DERM Journey Medical Corporation compare | 2.0× |
| CPIX Cumberland Pharmaceuticals Inc. compare | 2.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)